Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12906502 | 0.93 | DPP4 (0.43) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL920704 | 0.91 | DPP4 (0.44) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL7978548 | 0.88 | ALDH1A1 (0.35) | DPP4FAP | |
| SCHEMBL12906394 | 0.85 | DPP4 (0.45) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL3899520 | 0.83 | DPP4 (0.48) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL5434992 | 0.82 | DPP4 (0.52) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL5433194 | 0.80 | DPP4 (0.52) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL921182 | 0.78 | DPP4 (0.47) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL12906374 | 0.78 | DPP4 (0.46) | DPP4BTKJAK3KDM4DMAP4K4 | |
| SCHEMBL13647473 | 0.76 | DPP4 (0.47) | DPP4BTKJAK3KDM4DMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970442-A | Bicyclic pyrrole compound | DAINIPPON SUMITOMO PHARMA CO | 2011-02-09 | — | — | CN | disclosed |
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2264034-A1 | BICYCLIC PYRROLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | HPD, DPYD, PPIP5K2 | DPP4 907/4885BTK 4240/4885JAK3 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.